MAPT and Alzheimer disease: In particular, phosphorylated tau variants (p-tau181 (refs. 3,4), p-tau217 (refs. 5,6) and p-tau231 (ref. 7)) have shown high diagnostic performance in differentiating AD from other neurodegenerative disorders and have been validated against neuropathology7–9.